| Bioactivity | RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer[1][2]. |
| Name | RS5517 |
| CAS | 2227017-46-9 |
| Formula | C23H19ClN2O2 |
| Molar Mass | 390.86 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Saponaro C, et al. β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy. Oncogene. 2018 Jun;37(24):3301-3316. doi: 10.1038/s41388-018-0170-y. Epub 2018 Mar 19. [2]. Capdevielle C, et al. HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53. Neuro Oncol. 2020 Apr 15;22(4):550-562. |
RS5517
CAS: 2227017-46-9 F: C23H19ClN2O2 W: 390.86
RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for t
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.